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Abstract Id (DNA binding and/or differentiation) proteins
occur physiologically during ontogenesis and negatively reg-
ulate the activity of other helix-loop-helix (HLH) proteins. Id2
protein causes block of cells differentiation in the S phase of
the cell cycle and regulates the activity of Rb protein. The role
of Id2 protein in physiological cell cycle progression and in
neuroblastoma (NBL) pathogenesis was proposed by
Lasorella. The aim of the study was evaluation of Id2 expres-
sion and its prognostic significance in NBL cells coming from
primary tumors and evaluation of its prognostic significance,
and correlation of Id2 expression with known prognostic fac-
tors. Sixty patients with primary NBL treated from 1991 to
2005 were included in the analysis. We found 50 patients with
high and 10 patients with low intensity of Id2 expression. The
median percentage of NBL cells with Id2 expression was
88 %. We found no correlation between the number of NBL
cells or the intensity of Id2 expression and OS and DFS. In
patients with stage 4 NBL, almost all patients had high ex-
pression of Id2 and it was significantly more common than in
other disease stages (p=0,03). We found no correlation be-
tween Id2 expression and other known prognostic factor in
NBL patients. We assume that Id2 is not prognostic factor.
However, due to its abundant expression in most of NBL cells
and its role in cell cycle, it may be potential therapeutic target.
Exact knowledge of expression time may be helpful in
explaining mechanisms of oncogenesis.
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Introduction
Id (DNA binding and/or differentiation binding) proteins have
a helix-loop-helix (HLH) structure (Table 1). They occur
physiologically during ontogenesis and negatively regulate
the activity of other HLH proteins. Unlike other proteins from
the HLH family, Id proteins (Id1 – Id4) lack the DNA binding
basic domain. It results in the block of the formation of func-
tional dimers of transcription regulators with tissue-specific
differentiation regulators, so the cells differentiation is
blocked and the cells come into the phase S of the cell cycle
[1–6]. As the only protein from the HLH family, Id2 can also
physically interact with Rb protein and prevent its antiprolif-
erative activity. As an effect, Id2 can simultaneously control
cell differentiation and cell cycle progression [1–3, 5, 7, 8]. It
is assumed that, in the condition of abundant Id2 expression,
the increased amount of unphosphorylated pRb protein is not
sufficient for inhibition of cell cycle [2, 3, 7, 8]. During early
stages of cell differentiation all proteins from Id family are
expressed in many tissues and organs. The time and the level
of expression depend on tissues/organs and the stage of dif-
ferentiation [5, 9–11]. In the postnatal period Id2 expression is
described in some postmitotic neurons of the central nervous
system [9, 12, 14]. Id2 expression, as well as MYCN expres-
sion, is not physiologically found in normal adrenal glands
during postnatal period [15]. Id proteins are necessary for
maintaining the immaturity of progenitor cells and their pro-
liferation as long as the established point in their development
is reached [14, 16, 17]. This is especially important in control
of nervous system cells differentiation and coordination of
differentiation with definitive termination of cell proliferation
and irreversible block of cell cycle progression [3, 8, 9, 12, 14,
18–20]. There is also a hypothesis concerning the influence of
Id2 proteins on primary neoplastic cells (tumor stem cells). In
such a case the presence of Id2 protein even in the single
neoplastic cell could confirm its crucial role in tumor
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development [21, 22]. The high level of Id2 protein was found
in some NBL cell lines with MYCN amplification. Features
characteristic for cells with high activity of Myc family pro-
tein, as ability to enter the cell cycle without the presence of
growth factors and ability of cooperation with ras protein are
supposed to be dependent on Id2 protein function [14, 23].
Lasorella et al. found that excessive Id2 expression in neuro-
blastoma (NBL) cells is responsible for neoplastic transforma-
tion of precursor cells and its constant expression is required
for keeping malignant character of NBL cells [8, 15]. As Id2
expression is especially crucial for normal nervous cells de-
velopment the neoplastic cells coming from nervous system
might be more sensitive for abnormal Id2 expression [12, 13,
15, 18].
Material and Methods
The aim of the study was evaluation of Id2 expression in
neuroblastoma cells coming from primary tumors stored as
paraffin blocks taken from patients at diagnosis, evaluation
of its prognostic significance and correlation between Id2 ex-
pression and known prognostic factors. Sixty patients were
included in the analysis, treated for NBL in the Department
of Oncology and Hematology in Krakow from 1991–2005.
Observation was finished in June 2012. The characteristics of
patients are presented in Table 2. Analysis of the significance
of Id2 protein expression was performed both for the whole
group of patients and for subgroups defined according to cho-
sen established prognostic factors, as age, clinical stage of
disease and MYCN amplification (Table 3).
Id2 expression was evaluated with immunohistochemistry.
Staining was performed with rabbit anti-Id2 antibodies
(Zymed Laboratories Inc.) on silanized slides. According to
manufacturer guidelines, the optimal dilution of primary anti-
body was experimentally established as 1:100 and the time of
incubation as 45 min. The detection system was based on
peroxidase (EnVision + System-HRP®, DacoCytomation)
for use with rabbit primary antibodies, for evaluation in light
microscopy of paraffin embedded tissue. As the positive con-
trol NBL cell line SKNSH was used with known high Id2
expression. As the second control human testis was used, em-
bedded in paraffin. The double control system was chosen
because we wanted to compare staining procedures in the
samples prepared under the same conditions in our laboratory
(testis tissue, unlike the cell line, underwent the same
deparaffinization procedures and antigen unblocking). In neg-
ative control, no primary antibody was added. The percentage
of cells with Id2 expression was evaluated in the light micros-
copy. The intensity of Id2 staining was evaluated by compar-
ison with staining intensity of the positive control.
Estimations of the survival were performed using a
Kaplan-Meier method and compared with a log-rank test.
The comparisons between groups were performed by a chi-
square test (with Fisher’s exact test if necessary), Student’s t
test and Pearson correlation test. For all analyses the p values
less than 0.05 (p<0.05) were considered as statistically signif-
icant. Statistica® software packages were used for statistical
analysis.
The influence of intensity of Id2 expression and the per-
centage of NBL cells with Id2 expression on mortality and
therapy failures (initial progression or relapse) was evaluated.
Results
Among 60 NBL patients evaluated, we found 50 patients with
high and 10 children with low intensity of Id2 expression. The
percentage of NBL cells with the Id 2 expression was 1–
100 % (median 88 %, mean 77.5 %). In 53 patients (88 %)
the Id2 expression was found inmore then 50% of cells and in
28 (46.7 %) – in over 90 % (Fig. 1).
As the main aim of the study was the evaluation of Id2 as a
prognostic factor, we decided to exclude from the overall sur-
vival analysis the patients whose death was not caused by
Table 1 Abbreviations list
DFS disease free survival
HLH helix-loop-helix
Id DNA binding and/or differentiation protein
NBL neuroblastoma
OS overall survival
RT-PCR reverse transcription polymerase chain reaction
Table 2 Patient characteristic
Parameters Number of
patients (%)
Sex Boys 34 (57.0)
Girls 26 (43.0)
Age (months) Range 0,3 – 169
Median 24,5
Number of patients >12
months of age
41 (68.3)
Number of patients <12
months of age
19 (31.7)
Stage 1 0 (0.0)
2 6 (10.0)
3 17 (28.3)
4 31 (51.7)
4 s 6 (10.0)
MYCN amplification Present 12 (20.0)
Absent 46 (76.7)
No result 2 (3.3)
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NBL. Deaths occurred in 29 out of 50 patients (23 died of
NBL) and 3 out of 10 patients (all caused by NBL) with high
and low Id2 expression, respectively (chi-square, Fisher’s ex-
act test, p=0.19). Three-year OS was similar for both groups
(0.68 and 0.7 in the groups with low and high Id2 expression,
respectively). Five-year OS was higher in patients with low
Id2 expression, but the results were not statistically significant
(p=0.3). Therapy failure defined as early progression or re-
lapse occurred in 30 out of 50 children with high Id2 expres-
sion and 4 out of 10 children with low Id2 expression (chi-
square, Fisher’s exact test, p=1.0). No statistically significant
differences were found (p=0.15) for 3-year DFS (0.7 and
0.48) and 5-year DFS (0.7 and 0.4). In 41 evaluated patients
over 1 year of age, the percentage of NBL cells with Id2
expression was 1-100 % (mean: 73.3 %, median: 85 %). In
17 patients (41.5 %) the percentage of Id2 positive cells was
over 90 %. In children younger than 1 year of age (n=19) the
percentage of cells with Id2 expression was 50 %-100 %
(mean 86 %, median 90 %). In 9 patients (47.4 %) Id2 expres-
sion was found in over 90 % of cells. In patients with stage 4
NBL, only 2 among 31 patients had low expression of Id2 –
we did not perform comparative analysis. The percentage of
Id2 positive cells was 1–100 % (mean 74%, median 85%). In
patients with stage 4, in comparison to other stages, we found
significantly more common high expression of Id2 (p=0.03)
(Fig. 2). The number of cells with high Id2 expression was not
higher in patients in stage 4 (p=0.46). The percentage of Id2
positive cells in patients in stage 2, 3 or 4 s was 1–100 %
(mean 81.7 %, median 90 %). In this group of patients neither
intensity of Id2 expression nor percentage of Id2 positive cells
had influence on treatment outcomes (overall survival or dis-
ease relapse and progression). Among 12 patients with
MYCN amplification, only 1 had low Id2 expression. The
comparative analysis was not performed. The percentage of
Id2 positive cells in patients with MYCN amplification was
40–100 % (mean 81.2 %, median 97.5 %). Percentage of Id2
positive cells had influence on neither NBL deaths (p=0.75)
nor therapy failure (p=0.51) in this group of patients. In pa-
tients without MYCN amplification (n=46) the percentage of
Id2 positive cells was 1–100 % (mean 81.2 %, median
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Table 3 Treatment results depending on intensity of Id2 staining and
number of Id2 positive cells in the whole group of patients and defined
subgroups
Intensity of Id2
staining
Number of Id2
positive cells
p value
Age at diagnosis 0.39 0.53
Presence of MYCN
amplification
0.33 0.73
Whole group of patients
Deaths 0.19
OS 0.3
Therapy failures 1.0
DFS 0.15
Patients over 1 year of age
Deaths 0.35 0.79
OS 0.55
Therapy failures 0.58 0.07
DFS 0.53
Patients under 1 year of age
Deaths 0.57 0.06
OS 0.42
Therapy failures 0.21 0.86
DFS 0.19
Amplification of MYCN
Deaths 0.75
Therapy failures 0.51
No amplification of MYCN
Deaths 0.17 0.38
OS 0.2
Therapy failures 0.15 0.02*
DFS MYCN 0.13
*higher number of cells in children without therapy failures
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97.5 %). The intensity of Id2 expression was not different in
patients with and without MYCN amplification (p=0.33). In
the group with no amplification, 15/37 children with high Id2
expression and 2/9 children with low Id2 expression died of
NBL (p=0.17). Therapy failures occurred in 22/37 and 3/9
children, respectively (p=0.15). In patients with no MYCN
amplification, 3-year and 5-year OS and DFS were higher in
the group with low Id2 expression. However, the difference
was not statistically significant (p=0.2 for OS and p=0.13 for
DFS). Percentage of Id2 positive cells had no influence on
survival (p=0.39) and on therapy failures (p=0.2).
Number of cells with Id2 expression and intensity of Id2
expression in cells had no statistically significant influence on
mortality or therapy failures in the other groups of patients
distinguished on the basis of age, stage or status of MYCN
amplification. For the whole group and defined subgroups we
did not find any correlation between the percentage of cells
with Id2 expression and OS, DFS, levels of lactate dehydro-
genase (LDH), ferritin or neurospecific enolase (NSE).
Discussion
Extraordinary biological characteristics of NBL and diverse
clinical outcome are the reasons why neuroblastoma is the
focus of scientific interest [24–31]. One of the possible mech-
anisms responsible for oncogenesis is the dysfunction of pro-
teins responsible for growth and differentiation of cells, as Id
family proteins. They maintain stem cells pool of the nervous
cells and their cytoplasmic sequestration promotes neural dif-
ferentiation [32]. However, the results of studies concerning
the possible meaning of Id2 in NBL remains unclear. In the
study of Lasorella [15] they found correlation between expres-
sion of MYCN and Id2 protein with statistically significant
influence of expression of Id2 in at least 25 % of cells on OS
and DFS [3, 15]. Other studies did not confirmed these results.
Vandesompele et al. [33] evaluated ID2, MYCN and MYC
genes expression in NBL cell lines and did not confirm cor-
relation between mRNA ID2 and either MYCN or MYC.
There was no correlation between Id2 and patients’ prognosis.
However, there was a trend for better prognosis in patients
with Id2 level lower then the mean for the whole group.
Alaminos et al. [34] evaluated Id2 in the group of 99 patients
and 12 cell lines and did not reveal any correlation between
MYCN and Id2 and it had no influence on prognosis. Both
proteins and genes were evaluated by Wang et al. [35] in 170
patients and 10 cell lines and they were found in all evaluated
tumors and cell lines. Id2 did not correlate with clinical pa-
tients’ characteristic and it was expressed independently of
MYCN status; these results are consistent with the ones ob-
tained in our study. However, we found that almost all patients
withMYCN amplification had high Id2 expression, as had the
patients in stage 4 NBL. The differences concerning correla-
tion of Id2 withMYCN can be the result of different attitude to
MYCN interpretation (amplification vs prognosis) and
methods of Id2 evaluation (protein vs gene expression) [36,
37]. Differences in cell culture conditions can be also partially
responsible for the observed inconsistent results [33]. It has
been proved that Id2 expression in cell lines is induced by
hypoxia, what can partially explain the described dedifferen-
tiation of hypooxygenated NBL cells [38]. It should be also
pointed that during normal embryogenesis the appropriate
level of Id2 is crucial in the given time points, so probably
for correct interpretation of the significance of Id2 protein
expression it would be necessary to know the exact time point
of its expression [39].
In our study we found expression of Id2 protein in all
evaluated tumors, with 83.3 % of patients with high expres-
sion in most of the cells. As neither the exact level nor the
meaning of time of Id2 expression is confirmed to be infor-
mative, we assumed that each observed expression of Id2 will
be defined as positive. There are some studies indicating the
existence of neoplastic stem cells, in which the mechanisms
connected with Id2 expression can play a potential role in
creating and maintaining malignant phenotype of the cell. In
our material the intensity of Id2 expression was comparable in
all analyzed groups; however, and lack of statistical signifi-
cance may be the result of a small number of patients. After
analysis of the whole group and subgroups it cannot be con-
firmed that Id2 expression has prognostic significance in
NBL. In most of univariate analyses, neither level of expres-
sion nor number of cells with Id2 expression had statistically
significant influence on OS and DFS. However, almost all
children with MYCN amplification had high intensity of Id2
expression and more children with strong Id2 expression were
in stage 4 of disease.
It has been proved that inhibition of Id2 function is possible
in vitro, and it results in reduction of tumorigenic properties in
neuroblastoma cells and promotion of cells differentiation
Id2: 1 – high expression, 2 – low expression
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Fig. 2 Number of patients with high and low Id2 protein expression in
children with stage 4 and other stages (2, 3 and 4 s) of neuroblastoma
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[40–42]. Additionally, it has been proved that retinoic acid
treatment is associated with negative regulation of ID2mRNA
[43]. Because of common expression of Id2 in neuroblastic
tumors and its known role in nervous system development, it
may be a potential therapeutic target and it is necessary to
continue work explaining meaning of the level and time of
its expression in NBL cells.
Acknowledgments The project was supported by the Ministry of Sci-
ence and Higher Education research grant N406074 31/2881.
Open Access This article is distributed under the terms of the Creative
Commons Attribution License which permits any use, distribution, and
reproduction in any medium, provided the original author(s) and the
source are credited.
References
1. Benezra R, Davis RL, Lockshon D, Turner DL, Weintraub H (1990)
The protein Id: a negative regulator of helix-hoop-helix DNA binding
proteins. Cell 61(1):49–59
2. Iavarone A, Garg A, Lasorella A, Hsu J, Israel M (1994) The helix-
loop-helix protein Id2 enhances cell proliferation and binds to retino-
blastoma protein. Genes Dev 8:270–284
3. Lasorella A, Noseda M, Beyna M, Yokota Y, Iavarone A (2000) Id2
is a retinoblastoma protein target and mediates signaling by Myc
oncoproteins. Nature 407:592–598
4. Liu Y, Encinas M, Comella JX, Aldea M, Gallego C (2004) Basic
helix-loop-helix proteins bind to TrkB and p21cip promoters linking
dedifferentiation of hypoxic neuroblastoma cells. J Bioch Chem
24(7):2662–2672
5. Norton JD, Deed RW, Crags G, Sablitzky F (1998) Id helix-loop-
helix proteins in cell growth and differentiation. Trends Cell Biol 8:
58–65
6. Yokota Y (2001) Id and development. Oncogene 20:8290–8298
7. Iavarone A, Lasorella A (2004) Id2 proteins in neural cancer. Cancer
Lett 204:270–284
8. Lasorella A, Iavarone A, Israel MA (1996) Id2 specificity alters reg-
ulation of the cell cycle by tumor suppressor proteins. Mol Cell Biol
16(6):2570–2578
9. Riechmann V, Sablitzky F (1995) Mutually exclusive expression of
two dominant-negative helix-loop-helix (dnHLH) genes, Id4 and Id3,
in the developing brain of the mouse suggests distinct regulatory
roles of these dnHLH proteins during cellular proliferation and dif-
ferentiation of the nervous system. Cell Growth Differ 6(7):837–843
10. Zhu W, Dahmen J, Bulfone A, Rigolet M, Hernandez MC, Kuo WL,
Rubenstein JRL, Israel MA (1995) Id gene expression during devel-
opment and molecular cloning of the human Id-1 gene. Mol Brain
Res 30(2):312–326
11. Biggs J, Murphy EV, Israel MA (1992) A human Id-like helix-loop-
helix protein expressed during early development. Proc Natl Acad
Scie USA 89:1512–1516
12. Toma JG, El-Bizri H, Barnabe-Heider F, Aloyz R, Miler FD (2000)
Evidence that helix-loop-helix proteins collaborate with retinoblasto-
ma tumor suppressor protein to regulate cortical neurogenesis. J
Neurosc 20(20):7648–7656
13. Lasorella A, Iavarone A (2006) The protein ENH is a cytoplasmic
sequestration factor for Id2 in normal and tumor cells from the ner-
vous system. Proc Natl Acad Sci U S A 103(13):4976–4981
14. Lasorella A, Uo T, Iavarone A (2001) Id proteins at the cross-road of
development and cancer. Oncogene 20:8326–8333
15. Lasorella A, Boldrini R, Dominici C, Donfrancesco A, Yokota Y,
Inserra A, Iavarone A (2002) Id2 is critical for cellular proliferation
and is the oncogenic effector of N-Myc in human neuroblastoma.
Cancer Res 63:301–306
16. Tzeng SF (2003) Inhibitors of DNA binding in neural proliferation
and differentiation. Neurochem Res 28(10):45–52
17. Yokota Y, Mori S, Narumi O, Kitajima K (2001) In vivo function of a
differentiation inhibitor Id2. Life 51:207–214
18. Gleichmann M, Buchheim G, El-Bizri H, Yokota Y, Klockgether T,
Kuegler S, Bahr M, Weller M, Schulz JB (2002) Identification of
inhibitor-of-differentiation 2 (Id2) as a modular of neuronal apopto-
sis. J Neurochem 80:755–762
19. Lee EY, Hu N, Yuan SS, Cox LA, Bradley A, Lee WH, Herrup K
(1994) Dual roles of the retinoblastoma protein in cell cycle regula-
tion and neuron differentiation. Genes Dev 8:2008–2021
20. Chen XS, Zhang YH, Cai QY, Zyao ZX (2012) ID2: a negative
transcription factor regulating oligodnedroglia differentiation. J
Neurosc Res 90:925–932
21. Al-Haji M, Clarke MFL (2004) Self-renewal and solid tumor stem
cells. Oncogene 24:7273–7282
22. Freidenraich D, Stilwell D, Romero E, Wilkes D, Manova K, Basson
C, Benezra R (2004) Rescue of cardiac defects in ID knockout em-
bryos by injection of embryonic stem cells. Science 306:247–252
23. Lasorella A, Rothschild G, Yokota Y, Russel RG, Iavarone A (2005)
Id2 mediates tumor initiation, proliferation and angiogenesis in Rb
mutant mice. Mol Cell Biol 25(9):3563–3574
24. BalwierzW (2004) Strategie postępowania w nerwiaku zarodkowym
współczulnym. Przegl Lek 61(2):3–8
25. Berthold F, Kassenbohmer R, Zieschang J (1994) Multivariate eval-
uation of prognostic factors in localized neuroblastoma. Am J Pediatr
Hematol Oncol 16:107–115
26. Brodeur GM,Maris JM, Jamashiro DM (1997) Biology and genetics
of human neuroblastomas. J Pediatr Hematol Oncol 19:93–101
27. Brodeur GM, Seeger RC, Schwabb M, Varmus HE, Bishop JM
(1984) Amplifiaction of Myc-N in untreated human neuroblastoma
correlates with advanced disease stage. Science 224:1121–1124
28. Caron H (1995) Allelic loss of chromosome 1 and additional chro-
mosome 17 material are both unfavorable prognostic markers in neu-
roblastoma. Med Ped Oncol 24(4):215–221
29. Cohn SL, London WB, Huang D, Katzenstien HM, Salwen HR,
Reinhart T, Madafiglio J, Marshall GM, Norris MD, Haber M
(2000) MYCN expression is not prognostic of adverse outcome in
advance-stage neuroblastoma with nonamplified MYCN. J Clin
Oncol 18(21):3604–3613
30. Oude Luttikhuis MEM, Powell JA, Rees SA, Genus T, Chughtai S,
Ramani P, Mann JR, McCoville CM (2001) Neuroblastoma with 11q
loss and single MYCN copy comprise a biologically distinct group of
tumours with adverse prognosis. Brit J Cancer 85(4):531–537
31. Vandesompele J, Speleman F, Van Roy N, Laureys G, Brinkschmidt
C, Christiansen H, Lampert F, Lastowska M, Bown N, Pearson A,
Nicolsson JC, Ross F, Combarett V, Delattre O, Feuerstein DG,
Plantaz D (2001) Multicentre analysis of patterns of DNA gains
and loses in 204 neuroblastoma tumors: howmany genetic subgroups
are there? Med Ped Oncol 36:5–10
32. Iavarone A, Lasorella A (2006) ID proteins as targets in cancer and
tools in neurobiology. Trend Mol Med 12:588–594
33. Vandesompele J, Edsjo D, De Preter K, Axelson H, Speleman F,
Pahlman S (2003) ID2 expression in neuroblastoma does not corre-
late to MYCN levels. Oncogene 22:456–460
34. Alaminos M, Gerald WL, Cheung NKV (2005) Prognostic value of
MYCN and ID2 overexpression in neuroblastoma. Pediatr Blood
Cancer 45:909–915
35. Wang Q, Guo C, Hii G, Shusterman S, Mosse Y, Zhao H, Cnaan A,
Rappaport E, Hogarty MD, Marris JM (2003) ID2 expression is not
associated with MYCN amplification or expression in human neuro-
blastoma. Cancer Res 63:1631–1635
The role of Id2 protein in neuroblatoma in children 1003
36. Gebauer S, Yu AI, Omura-Minamisawa M, Batova A, Dicciani M
(2004) Expression profiles and clinical relationship of ID2,
CDKN1B and CDKN2B in primary neuroblastoma. Genes
Chromosomes Cancer 41:297–308
37. Raetz EA, Kim MK, Moos P, Carslon M, Bruggers C, Hooper DK,
Foot L, Liu T, Seeger R, Carroll WL (2003) Identification of genes
that are regulated transcriptionally by Myc in childhood tumors.
Cancer 98(4):841–853
38. Lofstedt T, Jogi A, Sigvardsson A, Gradin K, Poellinger L, Pahlman
S, Axelson H (2004) Indcution of ID2 expression by hypoxia-
inducible factor-1. A role in dedifferentiation of hypoxic neuroblas-
toma cells. J Biol Chem 279(38):39223–39231
39. Perk J, Iavarone A, Benezra R (2005) Id family of helix-loop-helix
protein in cancer. Nat Rev Cancer 5(8):603–614
40. Ciarapica R, Annibali L, Raimondi L, Savino M, Nasi S, Rota R
(2009) Targeting Id protein interactions by an engineered HLH
domains induces human neuroblastoma cell differentiation 13I and
neuroblastoma differentiation. Oncogene 28:1881–1891
41. Han W, Wu Z, Zhao Y, Meng Y, Si Y, Yang J, Fu X, Yu L
(2009) FHL2 interacts with and acts as a functional repressor
of Id2 in human neuroblastoma cells. Nucleic Acid Research
12(37):3996–4009
42. Hu JG, Wu XJ, Feng YF, Xi GM, Deng LX, Wang ZH, Wang R,
Shen L, Zhou JS, Lu HZ (2013) The molecular events involved in
oligodendrocyte precursor cell proliferation induced by the condi-
tioned medium from B104 neuroblastoma cells. Neurochem Res
38:601–609
43. Annibali D, Gioia U, Savino M, Laneve P, Caffarelli E, Nasi
S (2012) A new module in neural differentiation control: two
microRNAs upregulated by retinoic acid, miR-9 and −103,
target the differentiation inhibitor ID2. doi:10.1371/journal.
pone.0040269
1004 W. Aleksandra, B. Walentyna
